Navigation Links
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements
Date:7/21/2014

ge;
  • the ultimate outcome and results of integrating the operations of Valeant and Allergan, the ultimate outcome of Valeant's pricing and operating strategy applied to Allergan and the ultimate ability to realize synergies;
  • the effects of the proposed combination of Valeant and Allergan, including the combined company's future financial condition, operating results, strategy and plans;
  • the effects of governmental regulation on our business or potential business combination transactions;
  • the ability to obtain regulatory approvals and meet other conditions to the offer, including the necessary stockholder approval, on a timely basis;
  • Valeant's ability to sustain and grow revenues and cash flow from operations in our markets and to maintain and grow our customer base, the need for innovation and the related capital expenditures and the unpredictable economic conditions in the United States and other markets;
  • the impact of competition from other market participants;
  • the development and commercialization of new products;
  • the availability and access, in general, of funds to meet our debt obligations prior to or when they become due and to fund our operations and necessary capital expenditures, either through (i) cash on hand, (ii) free cash flow, or (iii) access to the capital or credit markets;
  • our ability to comply with all covenants in our indentures and credit facilities, any violation of which, if not cured in a timely manner, could trigger a default of our other obligations under cross-default provisions; and
  • the risks and uncertainties detailed by Allergan with respect to its business as described in its reports and documents filed with the SEC.
  • All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement.  Readers are cautioned not to
    '/>"/>

    SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
    2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
    3. Valeant Pharmaceuticals To Host Investor Day
    4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
    5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
    6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
    7. Valeant Pharmaceuticals Announces Management Change
    8. Valeant Pharmaceuticals To Syndicate Incremental Loans
    9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
    10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
    11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
    (Date:8/3/2015)... 2015 Par Pharmaceutical Companies, Inc. announced today ... August 7, 2015 at 9:00 a.m. EDT to review ... June 30, 2015.  Par is privately held and currently ... its filings with the Securities and Exchange Commission and ... by following the instructions at http://www.parpharm.com/financialinfo .  Par ...
    (Date:8/3/2015)... , Aug. 3, 2015   ConvergeHEALTH ... pharmaceutical company Allergan plc is expanding ... and Intermountain Healthcare to include women,s ... ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world clinical ... "We look forward to expanding our ...
    Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4
    ... Calif. and SPRINGFIELD, Va. Oct. 29 Varian Medical Systems, ... Foundation has placed an order for five Varian TrueBeam™ systems ... CURE Foundation, which placed the order in September, plans to ... the U.S. East Coast during 2011.   ...
    ... Accuray Incorporated (Nasdaq: ARAY ), a global ... Creekside Cancer Care on their use of the CyberKnife ... in the world to install and begin treating patients with ... and clinicians at Creekside Cancer Care quickly reported that average ...
    Cached Medicine Technology:CURE Foundation Selects Varian Medical Systems to Supply Radiotherapy Technology for Five New Cancer Centers 2CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 2CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 3CyberKnife® VSI™ System Expands Treatment Applications and Significantly Reduces Treatment Times 4
    (Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and ... chin. Kybella is similar to deoxycholic acid, which occurs naturally in the body and ... options to treat this area of the body. These are invasive procedures and very ...
    (Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
    (Date:8/3/2015)... Decatur, Illinois (PRWEB) , ... August 03, 2015 , ... ... (IBAM NA) effective July 31. , The acquisition includes all of IBAM NA’s ... the opportunity to have both, a robust regionally located business, as well as a ...
    (Date:8/3/2015)... ... August 03, 2015 , ... ... announced today that Joe Williams has joined its growing California employee benefits division. ... differentiated service model to his clients. Mr. Williams will be joining the newly ...
    (Date:8/3/2015)... ... August 03, 2015 , ... Cambia Health Solutions has promoted ... the company’s Medicare and Federal Employee Programs (FEP) lines of business. , ... for members. In this role, Scott is responsible for overseeing the growth, finance ...
    Breaking Medicine News(10 mins):Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2
    ... Highmark Blue Cross Blue Shield,United Concordia Companies, ... healthy smiles and lifestyles for Pittsburghers. Beginning at ... 19, a free clinic will,offer health information and ... For far too long, oral health has ...
    ... drug offers new hope , , FRIDAY, July 18 (HealthDay News) ... the search for treatments against Alzheimer,s disease. , In one ... The Lancet , an older drug called dimebon significantly improved ... failed to prevent the progression of Alzheimer,s -- even though ...
    ... 18 minSURG Corporation,producers of the TruFUSE(R) ... of minSURG International, Incorporated. The,international division has ... the TruFUSE procedure and products., CEO, ... Germany,Greece, South Korea, Netherlands, Singapore, Taiwan, Turkey ...
    ... is showing the benefits of resistance training in keeping older ... a postdoctoral research fellow with UQ and Blue Care, said ... age of 65 responded to resistance training. , "What ... improve muscle strength, power and functional performance." Dr Henwood said. ...
    ... the earliest events occurring immediately upon infection with HIV-I ... the immune system earlier than was previously understood. According ... the window of opportunity for successful intervention may be ... after transmission, as researchers had previously believed. , Appearing ...
    ... 2008 -- The legal and ethical issues facing medical ... than some other areas of medicine. Certain activities, such ... federal and state governments. Other activities, such as minimum ... state to state. , A number of distinguished ...
    Cached Medicine News:Health News:Highmark Blue Cross Blue Shield, United Concordia and Catholic Charities Join Forces to Offer Free Health, Dental Services This Saturday 2Health News:Alzheimer's Research Brings Progress, Setbacks 2Health News:Alzheimer's Research Brings Progress, Setbacks 3Health News:Alzheimer's Research Brings Progress, Setbacks 4Health News:minSURG(TM) Corporation Launches International Division 2Health News:The benefits of a little resistance for older adults 2Health News:HIV conquers immune system faster than previously realized 2Health News:HIV conquers immune system faster than previously realized 3Health News:Legal and ethical issues in medical physics 2Health News:Legal and ethical issues in medical physics 3Health News:Legal and ethical issues in medical physics 4Health News:Legal and ethical issues in medical physics 5Health News:Legal and ethical issues in medical physics 6Health News:Legal and ethical issues in medical physics 7
    The Vitatron Excellence SS+ lead series are endocardial silicone leads providing ease of handling and optimal pacing characteristics....
    ... The Vitatron Impulse II lead series ... designed to extend the longevity of ... efficient pacing. The high impedance of ... the small electrode surface, combined with ...
    CapSure SP Novus endocardial, tined pacing leads provide the stable, low pacing thresholds and large sensing potentials already proven with CapSure SP steroid-eluting leads but within an even smaller...
    The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
    Medicine Products: